Skip to main content

Table 3 Banff histopathological features at diagnosis of cABMR

From: Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection

 

Treatment

(N=23)

Control

(N=39)

P value

MVI (g+tc)

2.78 ± 1.35

2.87 ± 1.36

0.67

i

0.6 ± 0.78

0.56 ± 0.65

0.95

t

0.17 ± 0.49

0.25 ± 0.69

0.97

g

1.52 ± 0.94

1.4± 0.94

0.63

ptc

1.26 ± 0.86

1.4 ± 0.79

0.4

ah

1.43 ± 1.04

1.38 ± 1.1

0.91

cg

1.74 ± 0.83

1.83 ± 0.77

0.54

ci

1.52 ± 0.79

1.83 ± 0.88

0.17

ct

1.56 ± 0.73

1.67 ± 0.89

0.62

IFTA

1.61 ± 0.78

1.83 ± 0.84

0.27

cv

1.17 ± 0.83

1.39 ± 0.87

0.46

C4d deposition

19 (82.6%)

17 (43.6%)

0.01

acute cellular rejection

0

6

0.05

  1. Results are shown as mean ± SD or absolute frequencies (%) for quantitative and qualitative variables respectively. i interstitial inflammation, t tubulitis, g glomerulitis, ptc peritubular capillaritis, ah arterial hyalinosis, cg transplant glomerulopathy, ci interstitial fibrosis, ct tubular atrophy, IFTA interstitial fibrosis + tubular atrophy, cv vascular fibrous intimal thickening